Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity with Lanreotide Autogel/Depot (LAN) vs Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data

#1475

Introduction: TGR is a novel measure of tumor growth activity that may be more precise than RECIST for evaluating response to treatment of NETs.

Aim(s): To evaluate TGR in patients from CLARINET study.

Materials and methods: Patients with metastatic intestinal / pancreatic NETs received LAN 120mg or Pbo 4wkly for 96wks or until PD/death. TGR (% variation of tumor volume per month) was calculated from SLD of original target lesions (excluding new ones) on 2 CT scans during defined periods: 12 to 24wks prior to randomization vs baseline (pretreatment); and baseline vs each visit or between consecutive visits. We analyzed changes in TGR during treatment, and relationship of TGR during different periods and PFS outcomes.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Dromain C

Authors: Caplin M, Pavel M, Ruszniewski P, Liyanage N, Massien C,

Keywords: TGR, PFS,